Leukocyte Chemotactic Factor 2 (LECT2)-Associated Renal Amyloidosis: A Case Series

Murphy, Charles L.; Wang, Shuching; Kestler, Daniel P.; Larsen, Christopher P.; Benson, Don M.; Weiss, Deborah; Solomon, Alan

doi:10.1053/j.ajkd.2010.08.013

Cited by 71 publications

(72 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because LECT2 is involved in hepatocarcinogenesis and severe liver injury, it is possible that hepatocellular damage causes upregulation of LECT2 expression and consequently, ALECT2 amyloidosis (11). However, LECT2 plasma levels tested in a few patients with ALECT2 amyloidosis were found to be normal (16). DNA sequencing performed in 26 patients with ALECT2 amyloidosis did not detect any mutation in the LECT2 gene (5,10,11,16).…”

Section: Clinical Characteristicsmentioning

confidence: 87%

“…However, LECT2 plasma levels tested in a few patients with ALECT2 amyloidosis were found to be normal (16). DNA sequencing performed in 26 patients with ALECT2 amyloidosis did not detect any mutation in the LECT2 gene (5,10,11,16). Interestingly, all patients tested were homozygous for the G allele (5,10,11,16).…”

Section: Clinical Characteristicsmentioning

confidence: 91%

“…There have been only five reported patients who were younger than 50 years old at diagnosis, the youngest of whom was 33 years old with hepatic ALECT2 amyloidosis (11,12). Most patients with renal ALECT2 amyloidosis present with chronic renal insufficiency (5,12,16). The mean serum creatinine at diagnosis was 3 mg/dl in the series by Said et al Table 1).…”

Section: Affected Organsmentioning

confidence: 95%

“…DNA sequencing performed in 26 patients with ALECT2 amyloidosis did not detect any mutation in the LECT2 gene (5,10,11,16). Interestingly, all patients tested were homozygous for the G allele (5,10,11,16). It is possible that the change from isoleucine to valine in the LECT2 protein decreases its stability and allows it to undergo amyloidogenic conformational alterations ( Figure 1).…”

Section: Clinical Characteristicsmentioning

confidence: 99%

“…All reported Hispanic patients who disclosed their origin were of Mexican descent (12,16). Because Mexican Americans constitute the largest group of United States Hispanics (63%), it is still unknown if they are more likely to develop ALECT2 than Unites States Hispanics originating from other countries.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Leukocyte Cell–Derived Chemotaxin 2–Associated Amyloidosis

Nasr

Doğan

Larsen

2015

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

Section: Clinical Characteristicsmentioning

confidence: 87%

Section: Clinical Characteristicsmentioning

confidence: 91%

Section: Affected Organsmentioning

confidence: 95%

Section: Clinical Characteristicsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Leukocyte Cell–Derived Chemotaxin 2–Associated Amyloidosis

Nasr

Doğan

Larsen

2015

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

The molecular structure and role of LECT2 or CHM‐II in arthritis, cancer, and other diseases

Zhu

Bennett

et al. 2021

Journal Cellular Physiology

View full text Add to dashboard Cite

Leukocyte cell-derived chemotaxin-2 (LECT2 or LECT-2), also called chondromodulin II (ChM-II or CHM2) plays a versatile role in various tissues. It was first identified as a chemotactic factor to promote the migration of neutrophils. It was also reported as a hepatokine to regulate glucose metabolism, obesity, and nonalcoholic fatty liver disease. As a secreted factor, LECT2 binds to several cell surface receptors CD209a, Tie1, and Met to regulate inflammatory reaction, fibrogenesis, vascular invasion, and tumor metastasis in various cell types. As an intracellular molecule, it is associated with LECT2-mediated amyloidosis, in which LECT2 misfolding results in insoluble fibrils in multiple tissues such as the kidney, liver, and lung. Recently, LECT2 was found to be associated with the development of rheumatoid arthritis and osteoarthritis, involving the dysregulation of osteoclasts, mesenchymal stem cells, osteoblasts, chondrocytes, and endothelial cells in the bone microenvironment. LECT2 is implicated in the development of cancers, such as hepatocellular carcinoma via MET-mediated PTP1B/Raf1/ERK signaling pathways and is proposed as a biomarker. The mechanisms by which LECT2 regulates diverse pathogenic conditions in various tissues remain to be fully elucidated. Further research to understand the role of LECT2 in a tissue tropism-dependent manner would facilitate the development of LECT2 as a biomarker for diagnosis and therapeutic target.

show abstract

Shotgun‐proteomics‐based clinical testing for diagnosis and classification of amyloidosis

et al. 2013

View full text Add to dashboard Cite

Shotgun proteomics technology has matured in the research laboratories and is poised to enter clinical laboratories. However, the road to this transition is sprinkled with major technical unknowns such as long-term stability of the platform, reproducibility of the technology and clinical utility over traditional antibody-based platforms. Further, regulatory bodies that oversee the clinical laboratory operations are unfamiliar with this new technology. As a result, diagnostic laboratories have avoided using shotgun proteomics for routine diagnostics. In this perspectives article, we describe the clinical implementation of a shotgun proteomics assay for amyloid subtyping, with a special emphasis on standardizing the platform for better quality control and earning clinical acceptance. This assay is the first shotgun proteomics assay to receive regulatory approval for patient diagnosis. The blueprint of this assay can be utilized to develop novel proteomics assays for detecting numerous other disease pathologies.

show abstract

Leukocyte Chemotactic Factor 2 (LECT2)-Associated Renal Amyloidosis: A Case Series

Cited by 71 publications

References 19 publications

Leukocyte Cell–Derived Chemotaxin 2–Associated Amyloidosis

Leukocyte Cell–Derived Chemotaxin 2–Associated Amyloidosis

The molecular structure and role of LECT2 or CHM‐II in arthritis, cancer, and other diseases

Shotgun‐proteomics‐based clinical testing for diagnosis and classification of amyloidosis

Contact Info

Product

Resources

About